Zhuo Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhuo Zhang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Danqing Huang
Department of Neurology, Geriatric Hospital of Nanjing Medical University, Jiangsu Province Official Hospital, Nanjing, China
1 shared publication - Jiali Jin
Department of Neurology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210008, People’s Republic of China
1 shared publication - Lei Chen
Department of Physiology, Nanjing Medical University, 140 Hanzhong Road, Nanjing, Jiangsu, 210029, PR China
1 shared publication - Ling Chen
Department of Physiology, Nanjing Medical University, 140 Hanzhong Road, Nanjing, Jiangsu, 210029, PR China
1 shared publication - Meijuan Zhang
Department of Neurology Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China
1 shared publication - Siyuan Huang
The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, 22 Hankou Road, Nanjing, Jiangsu, 210093, PR. China
1 shared publication
Latest Publications
- Open Access
- 14 July 2011
- Published by Springer Nature in BMC Neuroscience
- Vol. 12 (1) , 67
Cocaine- and amphetamine-regulated transcript promotes the differentiation of mouse bone marrow-derived mesenchymal stem cells into neural cells
Background: Neural tissue has limited potential to self-renew after neurological damage. Cell therapy using BM-MSCs (bone marrow mesenchymal stromal cells) seems like a promising approach for the treatment of neurological diseases. However, the neural differentiation of stem cells influenced by massive factors and interactions is not well studied at present. Results: In this work, we isolated and identified MSCs from mouse bone marrow. Co-cultured with CART (0.4 nM) for six days, BM-MSCs were differentiated into neuron-like cells by the observation of optical microscopy. Immunofluorescence demonstrated that the differentiated BM-MSCs expressed neural specific markers including MAP-2, Nestin, NeuN and GFAP. In addition, NeuN positive cells could co-localize with TH or ChAT by double-labled immunofluorescence and Nissl bodies were found in several differentiated cells by Nissl stain. Furthermore, BDNF and NGF were increased by CART using RT-PCR. Conclusion: This study demonstrated that CART could promote the differentiation of BM-MSCs into neural cells through increasing neurofactors, including BNDF and NGF. Combined application of CART and BM-MSCs may be a promising cell-based therapy for neurological diseases.
- 14 July 2011
- Published by Springer Nature in BMC Neuroscience
- Vol. 12 (1) , 67
Open AccessCocaine- and amphetamine-regulated transcript promotes the differentiation of mouse bone marrow-derived mesenchymal stem cells into neural cells
Background: Neural tissue has limited potential to self-renew after neurological damage. Cell therapy using BM-MSCs (bone marrow mesenchymal stromal cells) seems like a promising approach for the treatment of neurological diseases. However, the neural differentiation of stem cells influenced by massive factors and interactions is not well studied at present. Results: In this work, we isolated and identified MSCs from mouse bone marrow. Co-cultured with CART (0.4 nM) for six days, BM-MSCs were differentiated into neuron-like cells by the observation of optical microscopy. Immunofluorescence demonstrated that the differentiated BM-MSCs expressed neural specific markers including MAP-2, Nestin, NeuN and GFAP. In addition, NeuN positive cells could co-localize with TH or ChAT by double-labled immunofluorescence and Nissl bodies were found in several differentiated cells by Nissl stain. Furthermore, BDNF and NGF were increased by CART using RT-PCR. Conclusion: This study demonstrated that CART could promote the differentiation of BM-MSCs into neural cells through increasing neurofactors, including BNDF and NGF. Combined application of CART and BM-MSCs may be a promising cell-based therapy for neurological diseases.